Hims & Hers Shares Face Critical Test Amid Growth Concerns

Recent developments have cast a shadow over Hims & Hers Health, Inc., with the telehealth provider’s stock experiencing significant pressure following a critical assessment from Bank of America. What appeared to be a promising growth trajectory has now encountered serious scrutiny from market analysts questioning the company’s future direction.

Quarterly Report Looms as Turning Point

All eyes are focused on November 3rd, when Hims & Hers is scheduled to release its third-quarter financial results. This announcement will serve as a crucial indicator of whether recent challenges represent temporary turbulence or signal a more fundamental shift in the company’s performance. The organization faces substantial pressure to meet its official guidance of $570 to $590 million for Q3 and $2.3 to $2.4 billion for the full 2025 fiscal year.

Analyst Report Triggers Market Reaction

The situation reached a critical point on October 10th, when shares of Hims & Hers plummeted 6.5% following the release of a damaging research note from Bank of America. Market strategists at the financial institution revealed concerning order trends that challenge the company’s established growth narrative.

Particularly alarming was the data showing September orders declined 16% year-over-year—a significant warning sign for a business that has historically benefited from consistently expanding customer demand. In direct response to these findings, Bank of America reduced its fourth-quarter revenue projection to $590 million, which stands 6.5% below current market consensus estimates.

Should investors sell immediately? Or is it worth buying Hims & Hers Health Registered (A)?

Fundamental Business Challenges Emerge

The issues appear to extend beyond a single month of weakness. Researchers identified two primary concerns: decelerating core growth and intensifying competitive pressures. Although second-quarter 2025 results initially impressed with strong top-line and bottom-line figures, underlying cracks in the business model were already becoming apparent.

While subscriber numbers continued to expand, the wholesale segment delivered substantially disappointing results. Simultaneously, gross margins contracted due to rising product costs—a trend that could potentially threaten long-term profitability if it persists.

Financial Projections Revised Downward

In light of these developments, earnings estimates for 2025 have already been adjusted downward by 6.3%. The upcoming quarterly report will provide critical evidence determining whether September’s weakness was an anomaly or the beginning of a structural slowdown for the telehealth provider.

The company now stands at a crossroads, with its ability to maintain its growth story dependent on demonstrating that recent order trends do not reflect a new normal for the business.